CoChat

The role of captodiamine in the withdrawal from long-term benzodiazepine treatment

Mercier-Guyon, C., Chabannes, J. P., Saviuc, P. · 2004 · Current Medical Research and Opinion

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVES: Discontinuation of benzodiazepines can be associated with the emergence of a withdrawal syndrome which compromises successful termination of treatment. The objective of the present study was to evaluate whether a six week administration of captodiamine during benzodiazepine discontinuation could prevent emergence of a benzodiazepine withdrawal syndrome and thus facilitate discontinuation of these drugs. SUBJECTS AND METHODS: A controlled, randomised, double-blind trial of captodiamine versus placebo was conducted in 81 subjects presenting mild to moderate anxiety and treated for at least 6 months with a stable dose of benzodiazepine. Each subject was gradually weaned from benzodiazepines over a 14 day period using a tapering dose schedule and received captodiamine (150 mg/d) or placebo for 45 days from the beginning of the weaning period. OUTCOME MEASURES: The primary outcome criterion was the extent of withdrawal symptoms assessed using the Tyrer Benzodiazepine Withdrawal Symptom Questionnaire. Secondary outcome criteria were; self-evaluation of tension, anxiety, drowsiness and slowing of physical and mental performance using visual analogue scales; quality of sleep using the Spiegel questionnaire; anxiety using the Hamilton Anxiety Rating Scale; and cognitive function using a driving stimulation test. RESULTS: Analysis of the primary study criterion revealed a statistically significant difference (p < 0.0001) in the emergence of withdrawal symptoms between the two groups in favour of captodiamine at two, six and eight weeks following initiation of therapy. These results were supported by significant beneficial effects of captodiamine on the majority of secondary outcome measures. The switch to captodiamine was associated with an improvement in vigilance, which may be an advantage for the overall safety of the anxiolytic treatment, for example with regard to road safety. Discontinuation of captodiamine was not associated with the emergence of rebound anxiety. CONCLUSION: Captodiamine represents an interesting strategy for achieving benzodiazepine substitution with a low risk of dependence or impairment of cognitive function. Further clinical studies addressing the anxiolytic activity and safety of captodiamine in such subjects are merited.

Overview

Integrity signals

Registry

Crossref · 10.1185/030079904125004457

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 44 references

Research works printed but not linked: 9

  1. Lister RG, 1988, Psychopharmacol Ser, 6, 117
  2. Garriot JC, 1977, J Forensic Sci, 22, 283
  3. Dietch J, 1983, Hosp Community Psychiatry, 34, 1139
  4. Rickels K, 1984, Psychopharmacol Bull, 20, 608
  5. Zarifian E, 1998, Bull Acad Natl Med, 182, 1439
  6. De Gier JJ, 1988, European Council (Pompidou Group) P-PG/Circrout (98), 1, 1
  7. Ansseau M, 1993, J Clin Psychiatry, 54, 189
  8. Weidmann H, 1953, J Pharmacol Exp Therap, 108, 201
  9. Pentney BH, 1960, Practitioner, 185, 218

Cited by

See all 24

Metadata

Authors
Mercier-Guyon, C., Chabannes, J. P., & Saviuc, P.
Affiliations
Centre Hospitalier Universitaire de Grenoble (FR)
Corresponding author
Mercier-Guyon, C.
Venue
Current Medical Research and Opinion
Published
2004-07-14
Volume
20
Issue
9
Pages
1347-1355
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2114226116
Cited by
24
References
43
Citations by year
2025: 2 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 1 · 2018: 2 · 2016: 1 · 2015: 1 · 2014: 1 · 2013: 2
FWCI
0.72
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
benzodiazepine withdrawal syndrome, benzodiazepine tapering, benzodiazepine discontinuation, anxiety, sustained attention, cognitive function, sleep quality, anxiolytics
MeSH terms
Adult, Anxiety, Benzodiazepines, Double-Blind Method, Ethylamines, Female, Humans, Male, Substance Withdrawal Syndrome, Sulfides, Anti-Anxiety Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of captodiamine in the withdrawal from long-term benzodiazepine treatment. https://app.cochat.ai/papers/10.1185/030079904125004457
The paper
Mercier-Guyon, C., Chabannes, J. P., & Saviuc, P. (2004). The role of captodiamine in the withdrawal from long-term benzodiazepine treatment. Current Medical Research and Opinion. https://doi.org/10.1185/030079904125004457

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.